Modality
ERT
MOA
ALKi
Target
FXIa
Pathway
Angiogenesis
Bladder CaFL
Development Pipeline
Preclinical
~Jun 2014
→ ~Sep 2015
Phase 1
~Dec 2015
→ ~Mar 2017
Phase 2
~Jun 2017
→ ~Sep 2018
Phase 3
~Dec 2018
→ ~Mar 2020
NDA/BLA
~Jun 2020
→ ~Sep 2021
Approved
Dec 2021
→ Jul 2029
ApprovedCurrent
NCT07217269
2,615 pts·Bladder Ca
2021-12→2029-07·Terminated
2,615 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2029-07-033.3y awayPh3 Readout· Bladder Ca
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
Approved
Termina…
Catalysts
Ph3 Readout
2029-07-03 · 3.3y away
Bladder Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07217269 | Approved | Bladder Ca | Terminated | 2615 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 |